全球罕見神經退化性疾病治療市場：規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計到 2034 年，罕見神經退化性疾病治療市場規模將從 2025 年的 5.4 億美元達到 9.6 億美元，並預計從 2026 年到 2034 年將以 6.49% 的複合年成長率成長。

受公眾意識提升、診斷能力增強和精準醫療進步的推動，全球罕見神經退化性疾病治療市場正穩步成長。亨廷頓氏舞蹈症、肌萎縮性側索硬化症（ALS）和罕見帕金森氏症候群等疾病日益受到臨床關注，促使製藥公司加強研發投入。政府支持、孤兒藥認定以及罕見疾病治療的獎勵也顯著促進了已開發地區和新興地區市場的擴張。

推動該市場發展的關鍵因素包括遺傳性神經系統疾病盛行率的上升、基因療法的進步以及生物技術公司與研究機構之間合作的加強。疾病修正治療與創新藥物遞送系統的結合正在加速患者獲得治療。此外，病患登記系統和病患權益倡導組織的擴展正在促進早期診斷和更有效治療方法的製定，從而為市場成長創造了有利環境。

未來，隨著個人化醫療和人工智慧診斷技術的融合，市場預計將快速擴張。 CRISPR基因編輯和幹細胞療法等新型技術在治療罕見神經退化性疾病方面具有巨大潛力。臨床試驗的增加和監管支持的加強將進一步加速創新，而全球醫療基礎設施的改善有望擴大治療的覆蓋範圍，尤其是在診斷不足的地區。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球罕見神經退化性疾病治療市場：依治療類型分類

• 市場分析、洞察與預測
• 酵素替代療法
• 基因治療
• 幹細胞療法
• 免疫調節療法
• 症狀治療

第5章：全球罕見神經退化性疾病治療市場：依適應症分類

• 市場分析、洞察與預測
• 阿茲海默症
• 帕金森氏症
• 多發性硬化症
• 肌萎縮側索硬化症（ALS）
• 亨丁頓舞蹈症

第6章：全球罕見神經退化性疾病治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 靜脈
• 鞘內腔
• 皮下
• 外用

第7章 全球罕見神經退化性疾病治療市場：依年齡層分類

• 市場分析、洞察與預測
• 兒童
• 成人
• 老年人

第8章：全球罕見神經退化性疾病治療市場：依藥理學分類

• 市場分析、洞察與預測
• 單株抗體
• 低分子化合物
• 胜肽
• 寡核苷酸
• 病毒載體

第9章：全球罕見神經退化性疾病治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和分銷通路合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • UCB
  • Roche
  • Gilead Sciences
  • Merck
  • Biogen
  • Sanofi
  • Lundbeck
  • Pfizer
  • Otsuka Pharmaceutical
  • GlaxoSmithKline
  • Novartis
  • AbbVie
  • Teva Pharmaceutical Industries

The Rare Neurodegenerative Disease Treatment Market size is expected to reach USD 0.96 Billion in 2034 from USD 0.54 Billion (2025) growing at a CAGR of 6.49% during 2026-2034.

The global rare neurodegenerative disease treatment market is witnessing steady growth due to increasing awareness, improved diagnostic capabilities, and advancements in precision medicine. Conditions such as Huntington's disease, amyotrophic lateral sclerosis (ALS), and rare forms of Parkinsonism are gaining more clinical attention, encouraging pharmaceutical companies to invest in research and development. Government support, orphan drug designations, and incentives for rare disease treatments are also significantly contributing to market expansion across developed and emerging regions.

Key drivers of this market include the rising prevalence of genetic neurological disorders, advancements in gene therapy, and increasing collaborations between biotech firms and research institutions. The development of disease-modifying therapies, coupled with innovative drug delivery systems, is accelerating treatment accessibility. Additionally, growing patient registries and advocacy groups are pushing for early diagnosis and better therapeutic solutions, creating a favorable environment for market growth.

Looking ahead, the market is expected to expand rapidly with the integration of personalized medicine and AI-driven diagnostics. Emerging technologies such as CRISPR gene editing and stem cell therapy hold immense potential for treating rare neurodegenerative diseases. Increased clinical trials and regulatory support will further boost innovation, while improved global healthcare infrastructure will enhance treatment reach, especially in underdiagnosed regions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

• Enzyme Replacement Therapy
• Gene Therapy
• Stem Cell Therapy
• Immunomodulatory Therapy
• Symptomatic Treatment

By Disease Indication

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Huntington's Disease

By Route of Administration

• Oral
• Intravenous
• Intrathecal
• Subcutaneous
• Topical

By Age Group

• Pediatric
• Adult
• Geriatric

By Pharmacology

• Monoclonal Antibodies
• Small Molecules
• Peptides
• Oligonucleotides
• Viral Vectors

COMPANIES PROFILED

• Eli Lilly and Company, , UCB, Roche, Gilead Sciences, Merck, Biogen, Sanofi, Lundbeck, Pfizer, Otsuka Pharmaceutical, GlaxoSmithKline, Novartis, AbbVie, Teva Pharmaceutical Industries
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment Type
• 4.2. Enzyme Replacement Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Stem Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunomodulatory Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Symptomatic Treatment Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Alzheimer's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parkinson's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Multiple Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Amyotrophic Lateral Sclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Huntington's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Intrathecal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Age Group
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY PHARMACOLOGY 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Pharmacology
• 8.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Small Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Peptides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Oligonucleotides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Viral Vectors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Treatment Type
  • 9.2.2 By Disease Indication
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Age Group
  • 9.2.5 By Pharmacology
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Treatment Type
  • 9.3.2 By Disease Indication
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Age Group
  • 9.3.5 By Pharmacology
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Treatment Type
  • 9.4.2 By Disease Indication
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Age Group
  • 9.4.5 By Pharmacology
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Treatment Type
  • 9.5.2 By Disease Indication
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Age Group
  • 9.5.5 By Pharmacology
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Treatment Type
  • 9.6.2 By Disease Indication
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Age Group
  • 9.6.5 By Pharmacology
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 UCB
  • 11.2.2 Roche
  • 11.2.3 Gilead Sciences
  • 11.2.4 Merck
  • 11.2.5 Biogen
  • 11.2.6 Sanofi
  • 11.2.7 Lundbeck
  • 11.2.8 Pfizer
  • 11.2.9 Otsuka Pharmaceutical
  • 11.2.10 GlaxoSmithKline
  • 11.2.11 Novartis
  • 11.2.12 AbbVie
  • 11.2.13 Teva Pharmaceutical Industries